Drug Database · Clinicians

Polyethylene glycol 3350 + Potassium chloride + Sodium bicarbonate + Sodium chloride

Brands (1) HydrilaxeShow all

Laxative PH FDA category
Fixed-dose combination.

Rx · Prescription drugHR · Household remedy2 PH products
Dispensing: Household remedy (HR) · Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: USE Relieves occasional constipation (irregularity) Generally produces a bowel movement in 1 to 3 days US FDA label

  • Use: Klor-Con is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. US FDA label

    Kidney dosing: Potassium chloride (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    Hypokalemia treatment: 40 to 100 mEq/day in divided doses, no more than 40 mEq per dose; prevention: about 20 mEq/day. Use IV potassium if serum potassium is below 2.5 mEq/L (label).
    CrCl 30–59 mL/min
    Reduced potassium excretion and a much higher risk of hyperkalemia: start at the low end of the dose range, especially with RAAS inhibitors or NSAIDs; monitor serum potassium frequently and kidney function periodically (label 8.7). IV concentrate: must be diluted; never IV push (see IV label).
    CrCl 15–29 mL/min
    Reduced potassium excretion and a much higher risk of hyperkalemia: start at the low end of the dose range, especially with RAAS inhibitors or NSAIDs; monitor serum potassium frequently and kidney function periodically (label 8.7). IV concentrate: must be diluted; never IV push (see IV label).
    CrCl <15 mL/min (not on dialysis)
    Reduced potassium excretion and a much higher risk of hyperkalemia: start at the low end of the dose range, especially with RAAS inhibitors or NSAIDs; monitor serum potassium frequently and kidney function periodically (label 8.7). Specialist input. IV concentrate: must be diluted; never IV push (see IV label).
    Hemodialysis (intermittent)
    No dialysis dose in label; potassium removal depends on the dialysate. Give only for documented hypokalemia, start low and check potassium frequently (label 8.7); specialist input. IV concentrate (2 mEq/mL) must be diluted before use; never give by IV push or undiluted (fatal arrhythmia and cardiac arrest reported). In kidney impairment potassium is retained: use the low end of the infusion rate in the IV product label, with ECG monitoring as needed, and recheck potassium after each replacement. Concentration and rate limits: see the IV product label.
    Peritoneal dialysis
    No PD dose in label. PD patients can become hypokalemic; replace by measured potassium, starting low (label 8.7); specialist input. Hypokalemia is a modifiable risk factor for PD peritonitis (ISPD 2022).
    CRRT
    No data in label; replacement guided by frequent potassium levels and CRRT fluid potassium. Specialist input.
    • Dialyzable? Potassium is removed by hemodialysis and peritoneal dialysis (label lists dialysis among hyperkalemia treatments).
    • Monitoring Serum potassium frequently in kidney impairment and periodically on maintenance; kidney function; magnesium, acid-base status and ECG in cardiac or kidney disease (label 2.1, 8.7).

    From the Potassium chloride monograph (renalcarematters.com, reviewed).

  • Use: to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. US FDA label

    Kidney dosing: Sodium bicarbonate (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    IV for metabolic acidosis (adults and children 2 years and older): 2 to 5 mEq/kg over 4 to 8 hours, by bicarbonate, total CO2, pH and clinical state (label). Treat the cause.
    CrCl 30–59 mL/min
    No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
    CrCl 15–29 mL/min
    No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
    CrCl <15 mL/min (not on dialysis)
    No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
    Hemodialysis (intermittent)
    No dose change; anuria raises the risk of fluid overload from the sodium load (label 5.1). Dialysate bicarbonate also corrects acidosis; coordinate with the dialysis prescription (clinical judgment).
    Peritoneal dialysis
    No dose change; watch sodium load and fluid status (label 5.1).
    CRRT
    No data in label. CRRT fluids are usually bicarbonate-buffered; added IV bicarbonate is a specialist decision guided by blood gases.
    • Dialyzable? Bicarbonate crosses dialysis membranes in both directions according to the dialysate bicarbonate concentration (physiology; not stated in label).
    • Monitoring Blood gases or serum bicarbonate, sodium, potassium (hypokalemia as acidosis corrects), fluid status, blood pressure, edema. Extravasation site (hypertonic solutions).

    From the Sodium bicarbonate monograph (renalcarematters.com, reviewed).

  • Use: INDICATIONS AND USAGE Intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient. US FDA label

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Powder for oral solution: 13.1 g/350.7 mg/178.5 mg/178.5 mg, 13.12 g/350.7 mg/178.5 mg/46.6 mg

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Polyethylene glycol 3350 + Potassium chloride + Sodium bicarbonate + Sodium chloride as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Polyethylene glycol 3350 + Potassium chloride + Sodium bicarbonate + Sodium chloride
Package insert
HydrilaxePolyethylene glycol 3350 + Sodium Chloride + Sodium bicarbonate +Potassium Chloride
13.12g/350.7mg/178.5mg/46.6mg powder for oral solutionPolyester film/ Aluminum film/ LDPE Film Printed laminated foil x 14g (Box of 10's)
Rx
BLISS GVS PHARMA LTD.India
Bliss Gvs Pharma Ltd.Importer: BLISS GVS PHARMA LTD.
DR-XY47012
Aug 12, 2030
NonePolyethylene Glycol 3350 + Sodium Chloride + Sodium Bicarbonate + Potassium Chloride
13.1 g/350.7 mg/178.5 mg/178.5 mg Powder for Oral SolutionAluminum Foil Sachet x 14 g (Box of 10's)
HR
Lloyd Laboratories, Inc.Philippines
—
DR-XY46686
Feb 4, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .